Highlights from ASH 2018 Annual Meeting:
At ASH in San Diego, the CML education session was entitled 'With Great Success Comes Great Responsibility'. Professors Jane Apperley, Timothy Hughes and Charles Craddock gave respective presentations on the treatment of CML with TKIs, molecular monitoring to aid clinical decision making and the role of transplantation in managing CML. Below are interviews from the presenters on their perspectives on the session.
These summaries are brought to you with support from Bristol Myers Squibb.
In addition, we are pleased to be able to offer you a complete scientific summary of the education session on CML. This also contains a summary of relevant abstracts on; TFR failure, resistance and new drug development.
Summaries of the ASH CML Education Session
The Argument for Using Imatinib in CML
Jane Apperley described the outcome of newly diagnosed patients newly treated with first or second generation TKIs. She discussed balancing the desire to achieve the deep molecular responses that permit trials of TKI discontinuation with the potential adverse effects of earlier use of the more potent TKI's, and provided pragmatic advice regarding treatment decisions.